Related Experiment Video

Updated: Sep 26, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice

Published on: November 1, 2015

[Systemic lupus erythematosus in children. I: clinical and age dependent evolutive characteristics]

Stela Goţia1, Aurica Rugina, Evelina Moraru

  • 1Facultatea de Medicină Clinica a II-a Pediatrie, Universitatea de Medicină şi Famacie Gr.T. Popa Iaşi.

Revista Medico-Chirurgicala a Societatii De Medici Si Naturalisti Din Iasi
|March 18, 2003
PubMed

Insights

Pediatric Systemic Lupus Erythematosus (SLE) presents differently based on age. Younger children often show prolonged fever and neurological issues, while older children exhibit more adult-like cutaneous and renal symptoms.

Area of Science:

  • Pediatric Rheumatology
  • Immunology
  • Systemic Autoimmune Diseases

Context:

  • Systemic Lupus Erythematosus (SLE) in children presents unique challenges in diagnosis and management.
  • Understanding age-dependent clinical manifestations is crucial for early intervention.

Purpose:

  • To delineate the distinct clinical and evolutive characteristics of pediatric SLE based on age groups.
  • To evaluate the utility of diagnostic criteria and scoring systems for early SLE diagnosis and relapse assessment in children.

Summary:

  • This retrospective study analyzed 14 children (4-16 years) with SLE, dividing them into two age groups: under 10 years and over 10 years.
  • Children under 10 often presented with prolonged fever and neurological issues, sometimes with absent antinuclear antibodies (ANA).
  • Children over 10 showed symptoms more typical of adult SLE, with dominant cutaneous and renal manifestations.

Impact:

  • Highlights age-specific patterns in pediatric SLE, aiding in earlier diagnosis.
  • Emphasizes the importance of established diagnostic criteria (ARA, 1982) and scoring systems (Mayer, 1998) for effective management and relapse evaluation.
  • Informs clinical practice for better outcomes in pediatric lupus patients.

Related Concept Videos

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...